# Sanderling Ventures

> Sanderling Ventures is a specialist biomedical venture capital firm founded by Robert G. McNeil in 1979. It finances early-stage businesses and supplies operating leadership, financial support and development expertise, with investments spanning therapeutics, medical devices, diagnostics and digital health. The firm reports supporting more than 90 biomedical companies.

- **Founded:** 1979
- **Headquarters:** San Mateo, United States
- **Founders:** Robert G. McNeil (Founder and former Managing Director)
- **Products:** Seed and early-stage biomedical investment, Operating leadership and financial support, Biomedical development support
- **Notable:** Reports supporting more than 90 biomedical companies since inception., Actimis progressed to initial human trials on one Series A round, according to Sanderling., Boehringer Ingelheim announced a staged Actimis acquisition in 2008 with a potential US$515 million value contingent on successful development.

## Products & services

- **Seed and early-stage biomedical investment** — Equity financing for new biomedical businesses, with capacity for follow-on participation and investment syndicate formation.
- **Operating leadership and financial support** — Temporary executive and CFO-level support, recruitment and planning for a transition to independent management.
- **Biomedical development support** — Technical and regulatory expertise, research relationships and strategic assistance for portfolio ventures.

## Achievements

- Reports supporting more than 90 biomedical companies since inception.
- Actimis progressed to initial human trials on one Series A round, according to Sanderling.
- Boehringer Ingelheim announced a staged Actimis acquisition in 2008 with a potential US$515 million value contingent on successful development.
- Pulsar Vascular, founded by Sanderling in 2005, was acquired by Codman Neuro’s affiliate in 2016.
- Torax Medical, co-founded by Sanderling, was acquired by Ethicon in 2017.
- Portfolio company Chimerix was acquired by Jazz Pharmaceuticals for approximately US$935 million in cash in April 2025; this is not Sanderling’s disclosed return.

## Latest updates

- **2026-02** — Follow-through on a former portfolio company: Jazz reported US$48 million in 2025 Modeyso sales following its August launch. These are Jazz product sales, not Sanderling revenue.
- **2025-08** — FDA granted accelerated approval to dordaviprone (Modeyso), the Chimerix-origin programme acquired by Jazz, for a defined previously treated H3 K27M-mutant diffuse midline glioma population.
- **2025-04** — Jazz completed its approximately US$935 million cash acquisition of portfolio company Chimerix on April 21.
- **2025-03** — Sanderling’s news page linked the announcement of Jazz’s planned acquisition of Chimerix.

## Links

- Website: https://www.sanderling.com/
- LinkedIn: https://www.linkedin.com/company/sanderling-ventures/
- Facebook: https://www.facebook.com/Sanderling-Ventures-328341890533648/

---

Profile page: https://yespress.io/sanderling-ventures
Published by YesPress — https://yespress.io
Last updated: 2026-10-27